<!DOCTYPE html>
<html lang="tr">
<head>
<link rel="alternate" hreflang="tr" href="https://uzunyasa.com/pages/blog/ramazanda-glp1-kullananlar-icin-oruc-rehberi.html">
<link rel="alternate" hreflang="x-default" href="https://uzunyasa.com/pages/blog/ramazanda-glp1-kullananlar-icin-oruc-rehberi.html">
<meta http-equiv="Content-Language" content="tr">
<link rel="icon" type="image/png" sizes="32x32" href="/favicon.png"><link rel="icon" type="image/png" sizes="16x16" href="/favicon-16.png">
<script>if(location.protocol!=="https:"&&location.hostname!=="localhost"&&location.hostname!=="127.0.0.1")location.replace("https://"+location.host+location.pathname+location.search+location.hash);</script>
<!-- Google tag (gtag.js) -->
<script async src="https://www.googletagmanager.com/gtag/js?id=G-QBM7E0EHFP"></script>
<script>
 window.dataLayer = window.dataLayer || [];
 function gtag(){dataLayer.push(arguments);}
 gtag('js', new Date());
 gtag('config', 'G-QBM7E0EHFP');
</script>
 <meta charset="UTF-8">
 <meta name="viewport" content="width=device-width, initial-scale=1.0">
 <title>Ramazanda GLP-1 Kullananlar Ä°Ã§in OruÃ§ Rehberi | UzunYaÅŸa</title>
    <meta property="og:image" content="https://uzunyasa.com/images/og-default.png">
 <meta name="description" content="GLP-1 ilaÃ§larÄ±yla Ramazan orucunu gÃ¼venle tutmanÄ±n bilimsel rehberi. Ä°laÃ§ zamanlamasÄ±, hipoglisemi Ã¶nlemi, protein hedefleri ve pratik Ã¶neriler. Semaglutid ve Tirzepatid kullanÄ±cÄ±larÄ± iÃ§in kapsamlÄ± kÄ±lavuz.">
 <link rel="preconnect" href="https://fonts.googleapis.com">
 <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
 <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700;800&family=Playfair+Display:wght@500;600&display=swap" rel="stylesheet">
 <link rel="preload" href="../../styles/main.css" as="style">
 <link rel="stylesheet" href="../../styles/main.css">
 <link rel="preload" href="../../styles/animations.css" as="style">
 <link rel="stylesheet" href="../../styles/animations.css">
 <style>
 article { max-width: 800px; margin: 0 auto; padding: 7rem 2rem 4rem; }
 .post-meta-top { display: flex; gap: 1rem; flex-wrap: wrap; margin-bottom: 1.5rem; }
 .post-category { display: inline-block; background: #EC4899; color: white; padding: 0.4rem 1rem; border-radius: 20px; font-size: 0.8rem; font-weight: 600; }
 .reading-time { color: var(--text-gray); font-size: 0.9rem; }
 h1 { font-family: 'Playfair Display', serif; font-size: 2.5rem; font-weight: 600; line-height: 1.2; margin-bottom: 1rem; color: var(--text); }
 .subtitle { font-size: 1.15rem; color: var(--text-gray); margin-bottom: 2rem; line-height: 1.6; }
 .featured-image { width: 100%; height: 300px; background: linear-gradient(135deg, rgba(236,72,153,0.8), rgba(219,39,119,0.8)), url("https://images.unsplash.com/photo-1631549916768-4119b2e5f926?w=800&q=80") center/cover; border-radius: 16px; margin-bottom: 2rem; display: flex; align-items: center; justify-content: center; }
 .featured-image span { font-size: 4rem; }
 .toc { background: white; border: 1px solid #e5e7eb; border-radius: 12px; padding: 1.5rem; margin-bottom: 2rem; }
 .toc h3 { font-size: 1rem; font-weight: 600; margin-bottom: 1rem; color: var(--primary); }
 .toc ul { list-style: none; }
 .toc li { margin-bottom: 0.5rem; }
 .toc a { color: var(--text-gray); text-decoration: none; font-size: 0.9rem; }
 .toc a:hover { color: var(--primary); }
 .content p { margin-bottom: 1.5rem; font-size: 1.05rem; }
 .content h2 { font-size: 1.6rem; font-weight: 700; margin: 3rem 0 1rem; color: var(--primary); padding-top: 1rem; border-top: 1px solid #e5e7eb; }
 .content h3 { font-size: 1.25rem; font-weight: 600; margin: 2rem 0 0.75rem; color: var(--text); }
 .content ul, .content ol { margin: 1.5rem 0; padding-left: 1.5rem; }
 .content li { margin-bottom: 0.5rem; font-size: 1.02rem; }
 .content strong { color: var(--text); }
 .info-box { background: #eff6ff; border-left: 4px solid #3b82f6; padding: 1.25rem; border-radius: 0 12px 12px 0; margin: 1.5rem 0; }
 .warning-box { background: #fef3c7; border-left: 4px solid #f59e0b; padding: 1.25rem; border-radius: 0 12px 12px 0; margin: 1.5rem 0; }
 .success-box { background: #f0fdf4; border-left: 4px solid #10b981; padding: 1.25rem; border-radius: 0 12px 12px 0; margin: 1.5rem 0; }
 .quote-box { background: #faf5ff; border-left: 4px solid #8b5cf6; padding: 1.25rem; border-radius: 0 12px 12px 0; margin: 1.5rem 0; font-style: italic; }
 .stat-grid { display: grid; grid-template-columns: repeat(auto-fit, minmax(150px, 1fr)); gap: 1rem; margin: 2rem 0; }
 .stat-card { background: white; border: 1px solid #e5e7eb; border-radius: 12px; padding: 1.25rem; text-align: center; }
 .stat-card .number { font-size: 1.75rem; font-weight: 800; color: var(--primary); }
 .stat-card .label { font-size: 0.8rem; color: var(--text-gray); margin-top: 0.25rem; }
 table { width: 100%; border-collapse: collapse; margin: 1.5rem 0; font-size: 0.95rem; }
 th, td { padding: 0.75rem; text-align: left; border-bottom: 1px solid #e5e7eb; }
 th { background: #f8fafc; font-weight: 600; color: var(--primary); }
 .cta-box { background: linear-gradient(135deg, var(--primary), #2a7d83); color: white; padding: 2rem; border-radius: 16px; text-align: center; margin: 3rem 0; }
 .cta-btn { display: inline-block; background: white; color: var(--primary); padding: 0.75rem 1.5rem; border-radius: 8px; text-decoration: none; font-weight: 600; }
 .author-box { display: flex; align-items: center; gap: 1rem; padding: 1.5rem; background: white; border-radius: 12px; border: 1px solid #e5e7eb; margin: 2rem 0; }
 .author-avatar { width: 60px; height: 60px; background: var(--primary); border-radius: 50%; display: flex; align-items: center; justify-content: center; color: white; font-weight: 700; }
 .author-info h4 { font-weight: 600; margin-bottom: 0.25rem; }
 .author-info p { font-size: 0.85rem; color: var(--text-gray); }
 
 @media (max-width: 640px) { h1 { font-size: 1.8rem; } article { padding: 6rem 1rem 3rem; } .stat-grid { grid-template-columns: repeat(2, 1fr); } }
 
 .key-stat-box { background: linear-gradient(135deg, #f0fdfa, #ecfdf5); border-left: 5px solid #0D7377; border-radius: 0 16px 16px 0; padding: 1.5rem 2rem; margin: 2rem 0; display: flex; align-items: center; gap: 1.25rem; }
 .key-stat-box .ks-number { font-size: 2.5rem; font-weight: 800; color: #0D7377; line-height: 1; white-space: nowrap; }
 .key-stat-box .ks-context { font-size: 0.95rem; color: #195157; line-height: 1.5; }
 .key-stat-box.accent { border-left-color: #E8963E; background: linear-gradient(135deg, #fffbeb, #fef3c7); }
 .key-stat-box.accent .ks-number { color: #E8963E; }
 .key-stat-box.warning { border-left-color: #f59e0b; background: linear-gradient(135deg, #fffbeb, #fef3c7); }
 .key-stat-box.warning .ks-number { color: #f59e0b; }
 @media (max-width: 640px) { .key-stat-box .ks-number { font-size: 1.8rem; } .key-stat-box { flex-direction: column; text-align: center; } }
 
 .evidence-label { display: inline-block; padding: 0.2rem 0.6rem; border-radius: 12px; font-size: 0.8rem; font-weight: 600; margin-left: 0.5rem; }
 .evidence-high { background: #dcfce7; color: #166534; }
 .evidence-moderate { background: #fef3c7; color: #92400e; }
 .evidence-low { background: #fecaca; color: #991b1b; }
 </style>

    <meta property="og:title" content="Ramazanda GLP-1 Kullananlar Ä°Ã§in OruÃ§ Rehberi">
    <meta property="og:description" content="GLP-1 ilaÃ§larÄ±yla Ramazan orucunu gÃ¼venle tutmanÄ±n bilimsel rehberi. Ä°laÃ§ zamanlamasÄ±, hipoglisemi Ã¶nlemi, protein hedefleri ve pratik Ã¶neriler. Semaglutid ve Tirzepatid kullanÄ±cÄ±larÄ± iÃ§in kapsamlÄ± kÄ±lavuz.">
    <meta property="og:type" content="article">
    <meta property="og:url" content="https://uzunyasa.com/pages/blog/ramazanda-glp1-kullananlar-icin-oruc-rehberi.html">
    <meta property="og:image" content="https://uzunyasa.com/images/og-default.png">
    <meta property="og:site_name" content="UzunYaÅŸa">
    <meta property="og:locale" content="tr_TR">
    <meta name="twitter:card" content="summary_large_image">
    <meta name="twitter:title" content="Ramazanda GLP-1 Kullananlar Ä°Ã§in OruÃ§ Rehberi">
    <meta name="twitter:description" content="GLP-1 ilaÃ§larÄ±yla Ramazan orucunu gÃ¼venle tutmanÄ±n bilimsel rehberi. Ä°laÃ§ zamanlamasÄ±, hipoglisemi Ã¶nlemi, protein hedefleri ve pratik Ã¶neriler. Semaglutid ve Tirzepatid kullanÄ±cÄ±larÄ± iÃ§in kapsamlÄ± kÄ±lavuz.">
    <link rel="canonical" href="https://uzunyasa.com/pages/blog/ramazanda-glp1-kullananlar-icin-oruc-rehberi.html">
<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "Article",
  "headline": "Ramazanda GLP-1 Kullananlar Ä°Ã§in OruÃ§ Rehberi | UzunYaÅŸa",
  "description": "GLP-1 ilaÃ§larÄ±yla Ramazan orucunu gÃ¼venle tutmanÄ±n bilimsel rehberi. Ä°laÃ§ zamanlamasÄ±, hipoglisemi Ã¶nlemi, protein hedefleri ve pratik Ã¶neriler. Semaglutid ve Tirzepatid kullanÄ±cÄ±larÄ± iÃ§in kapsamlÄ± kÄ±lavuz.",
  "author": {
    "@type": "Organization",
    "name": "UzunYaÅŸa",
    "url": "https://uzunyasa.com"
  },
  "publisher": {
    "@type": "Organization",
    "name": "UzunYaÅŸa",
    "logo": {
      "@type": "ImageObject",
      "url": "https://uzunyasa.com/images/logo-icon-new.png"
    }
  },
  "datePublished": "2026-02-25",
  "dateModified": "2026-02-25",
  "mainEntityOfPage": "https://uzunyasa.com/pages/blog/ramazanda-glp1-kullananlar-icin-oruc-rehberi.html",
  "image": "https://uzunyasa.com/images/og-default.png",
  "keywords": "Ramazan, GLP-1, oruÃ§, <a href="glp1-tam-rehber.html" style="color:#0D7377; text-decoration:underline; text-decoration-color:rgba(13,115,119,0.3); text-underline-offset:2px;">semaglutid</a>, <a href="tirzepatide-yeni-nesil-kilo-verme-ilacinin-bilimsel-gercekle.html" style="color:#0D7377; text-decoration:underline; text-decoration-color:rgba(13,115,119,0.3); text-underline-offset:2px;">tirzepatid</a>, diyabet, obezite, hipoglisemi, protein, dehidrasyon"
}
</script>
</head>
<body>
 <header class="header">
 <div class="header-inner">
 <a href="../../index.html"><img src="../../images/logo.svg" alt="UzunYaÅŸa" class="logo-img"></a>
 <a href="../blog.html" class="back-link">â† Blog</a>
 </div>
 </header>

 <article>
 <div class="post-meta-top">
 <span class="post-category">ğŸŒ™ Ramazan Rehberi</span>
 <span class="reading-time">â± 15 dk okuma â€¢ Åubat 2026</span>
 </div>
 
 <h1>Ramazanda GLP-1 Kullananlar Ä°Ã§in OruÃ§ Rehberi</h1>
 <p class="subtitle">GLP-1 ilaÃ§larÄ±yla Ramazan orucunu gÃ¼venle tutmanÄ±n bilimsel rehberi. Ä°laÃ§ zamanlamasÄ±, hipoglisemi Ã¶nlemi, protein hedefleri ve pratik Ã¶neriler. Semaglutid ve Tirzepatid kullanÄ±cÄ±larÄ± iÃ§in kapsamlÄ± kÄ±lavuz.</p>

 <div class="featured-image">
  <span>ğŸŒ™</span>
 </div>

 <div class="toc">
 <h3>ğŸ“‹ Ä°Ã§indekiler</h3>
 <ul>
 <li><a href="#giris">GiriÅŸ: TÃ¼rkiye'de Durum</a></li>
 <li><a href="#guvenlik">GLP-1 ile Orucun GÃ¼venliÄŸi</a></li>
 <li><a href="#zamanlamasi">Ä°laÃ§ ZamanlamasÄ± Stratejisi</a></li>
 <li><a href="#hipoglisemi">Hipoglisemi Riski ve Ã–nlemler</a></li>
 <li><a href="#dehidrasyon">Dehidrasyon KorunmasÄ±</a></li>
 <li><a href="#protein">Protein Hedefleri</a></li>
 <li><a href="#pratik">Pratik Ã–neriler</a></li>
 <li><a href="#doktor">Doktor KontrolÃ¼</a></li>
 </ul>
 </div>

 <div class="content">
 <div class="key-stat-box accent"><span class="ks-number">32%</span><span class="ks-context">TÃ¼rkiye'de obezite oranÄ± (OECD 2024) â€” Avrupa'nÄ±n en yÃ¼ksek oranÄ±. Ramazan 2026, 17 Åubat'ta baÅŸlÄ±yor ve milyonlarca obez TÃ¼rk vatandaÅŸÄ± hem oruÃ§ tutmak hem de GLP-1 tedavisini sÃ¼rdÃ¼rmek istiyor.</span></div>

 <h2 id="giris">GiriÅŸ: TÃ¼rkiye'de Durum</h2>
 <p>Ramazan 2026, 17 Åubat Pazartesi gÃ¼nÃ¼ baÅŸlayacak. Bu yazÄ±nÄ±n hazÄ±rlandÄ±ÄŸÄ± tarih itibarÄ±yla Ramazan'Ä±n 7. gÃ¼nÃ¼ndeyiz. TÃ¼rkiye'de obezite oranÄ±nÄ±n %32'ye ulaÅŸtÄ±ÄŸÄ± (OECD 2024) bir dÃ¶nemde, binlerce hasta hem GLP-1 ilaÃ§larÄ± kullanÄ±yor hem de Ramazan orucunu tutmak istiyor.</p>

 <p>GLP-1 reseptÃ¶r agonistleri (Ozempic, Wegovy, Mounjaro, Zepbound) son yÄ±llarda obezite ve tip 2 diyabet tedavisinde devrim yarattÄ±. Ancak Ramazan ayÄ±nda bu ilaÃ§larÄ± gÃ¼venle kullanmak Ã¶zel bir planlama gerektiriyor.</p>

 <div class="warning-box">
 <strong>âš ï¸ Ã–nemli UyarÄ±:</strong> Bu rehber genel bilgi amaÃ§lÄ±dÄ±r. GLP-1 ilaÃ§larÄ± reÃ§eteli ilaÃ§lardÄ±r ve Ramazan Ã¶ncesi mutlaka doktorunuzla gÃ¶rÃ¼ÅŸmeniz gerekir. Orucun size uygun olup olmadÄ±ÄŸÄ±nÄ± sadece doktorunuz belirleyebilir.
 </div>

 <h2 id="guvenlik">GLP-1 ile Orucun GÃ¼venliÄŸi</h2>

 <div class="key-stat-box"><span class="ks-number">%38</span><span class="ks-context">DPP-4 inhibitÃ¶rlerine kÄ±yasla GLP-1 agonistlerinin hipoglisemi riskini azaltma oranÄ± (OR 0.38, %95 GA 0.26-0.55, p&lt;0.00001) â€” systematic review bulgusu ğŸŸ¢</span></div>

 <h3>Bilimsel KanÄ±tlar</h3>
 <p>2024 yÄ±lÄ±nda yayÄ±mlanan kapsamlÄ± bir narrative review <span class="evidence-label evidence-high">ğŸŸ¢ YÃ¼ksek KanÄ±t</span>, GLP-1 agonistlerinin Ramazan ayÄ±nda kullanÄ±mÄ±nÄ±n gÃ¼venli olduÄŸunu gÃ¶sterdi:</p>

 <ul>
 <li><strong>Hipoglisemi riski dÃ¼ÅŸÃ¼k:</strong> SÃ¼lfanÃ¼rea ile karÅŸÄ±laÅŸtÄ±rÄ±ldÄ±ÄŸÄ±nda belirgin ÅŸekilde daha az hipoglisemi</li>
 <li><strong>HbA1c iyileÅŸmesi:</strong> Ramazan ayÄ±nda bile glisemik kontrol devam ediyor</li>
 <li><strong>Kilo kaybÄ± sÃ¼rekliÄŸi:</strong> OruÃ§ periyodunda da kilo vermeye devam</li>
 <li><strong>Kan basÄ±ncÄ± faydasÄ±:</strong> KardiyovaskÃ¼ler parametrelerde iyileÅŸme</li>
 </ul>

 <h3>Hangi Hastalar Ä°Ã§in Uygun?</h3>
 
 <div class="success-box">
 <p><strong>âœ… DÃ¼ÅŸÃ¼k Risk (OruÃ§ Tutabilir):</strong></p>
 <ul>
 <li>Tip 2 diyabeti iyi kontrol altÄ±nda (HbA1c &lt;7%)</li>
 <li>GLP-1 monoterapisi veya metformin kombinasyonu</li>
 <li>Son 3 ayda ciddi hipoglisemi yok</li>
 <li>Komplikasyonsuz seyir</li>
 </ul>
 </div>

 <div class="warning-box">
 <p><strong>âš ï¸ YÃ¼ksek Risk (OruÃ§ Ã–nerilmez):</strong></p>
 <ul>
 <li>Tip 1 diyabet</li>
 <li>KontrolsÃ¼z tip 2 diyabet (HbA1c &gt;9%)</li>
 <li>Son 3 ayda ciddi hipoglisemi Ã¶ykÃ¼sÃ¼</li>
 <li>Diyabetik komplikasyonlar (nefropati, retinopati)</li>
 <li>Hamilelik veya emzirme</li>
 </ul>
 </div>

 <h2 id="zamanlamasi">Ä°laÃ§ ZamanlamasÄ± Stratejisi</h2>

 <h3>HaftalÄ±k Ä°laÃ§lar (Semaglutid, Tirzepatid)</h3>
 
 <table>
 <tr><th>Ä°laÃ§</th><th>Normal Uygulama</th><th>Ramazan Ã–nerisi</th><th>AÃ§Ä±klama</th></tr>
 <tr><td><strong>Ozempic/Wegovy</strong><br>(Semaglutid)</td><td>Haftada 1 kez</td><td>Ä°ftar sonrasÄ± 2-3 saat</td><td>Mide doluyken daha az bulantÄ±</td></tr>
 <tr><td><strong>Mounjaro/Zepbound</strong><br>(Tirzepatid)</td><td>Haftada 1 kez</td><td>Ä°ftar sonrasÄ± 2-3 saat</td><td>GI yan etkiler azalÄ±r</td></tr>
 </table>

 <div class="info-box">
 <strong>ğŸ’¡ Pratik Ä°pucu:</strong> HaftalÄ±k ilaÃ§larÄ± her zaman aynÄ± gÃ¼n yapÄ±n (Ã¶rneÄŸin Cumartesi akÅŸamlarÄ±). Bu ÅŸekilde plazma dÃ¼zeyleri stabil kalÄ±r ve yan etkiler Ã¶ngÃ¶rÃ¼lebilir olur.
 </div>

 <h3>GÃ¼nlÃ¼k Ä°laÃ§lar</h3>
 
 <p><strong>Rybelsus (Oral Semaglutid):</strong> Sahurda, yemekten en az 30 dakika Ã¶nce, az su ile alÄ±n. 30 dakika boyunca hiÃ§bir ÅŸey yemeyin/iÃ§meyin.</p>

 <p><strong>Saxenda (Liraglutid):</strong> Ä°ftar Ã¶ncesi 1-2 saat veya yatmadan Ã¶nce uygulanabilir. GÃ¼nlÃ¼k rutininizi deÄŸiÅŸtirmeyin.</p>

 <h3>Doz AyarlamasÄ±</h3>
 
 <div class="warning-box">
 <strong>ğŸš« Ramazan OrtasÄ±nda Doz DeÄŸiÅŸtirmeyin:</strong><br>
 Ramazan ayÄ± boyunca mevcut dozunuzda kalmaya devam edin. Doz artÄ±rÄ±mlarÄ± Ramazan sonrasÄ±na ertelenmeli. Bu yaklaÅŸÄ±m dehidrasyon riskini azaltÄ±r ve orucunuzu daha kolay geÃ§irmenizi saÄŸlar.
 </div>

 <h2 id="hipoglisemi">Hipoglisemi Riski ve Ã–nlemler</h2>

 <div class="key-stat-box warning"><span class="ks-number">%11</span><span class="ks-context">LIRA-Ramadan Ã§alÄ±ÅŸmasÄ±nda liraglutid grubunda semptomatik hipoglisemi oranÄ± â€” sÃ¼lfanÃ¼rea grubunda %18'e kÄ±yasla belirgin dÃ¼ÅŸÃ¼k (p&lt;0.001) ğŸŸ¢</span></div>

 <h3>Hipoglisemi Belirtileri</h3>
 <ul>
 <li>Titreme, Ã§arpÄ±ntÄ±</li>
 <li>Terleme</li>
 <li>BaÅŸ dÃ¶nmesi</li>
 <li>KonfÃ¼zyon, konsantrasyon bozukluÄŸu</li>
 <li>AÃ§lÄ±k hissi, mide bulantÄ±sÄ±</li>
 </ul>

 <h3>Risk FaktÃ¶rleri</h3>
 <ul>
 <li>Ä°nsÃ¼lin veya sÃ¼lfanÃ¼rea ile kombine kullanÄ±m</li>
 <li>YaÅŸlÄ±lÄ±k (&gt;65 yaÅŸ)</li>
 <li>BÃ¶brek yetmezliÄŸi</li>
 <li>Uzun sÃ¼reli diyabet (&gt;10 yÄ±l)</li>
 <li>GeÃ§irilmiÅŸ hipoglisemi Ã¶ykÃ¼sÃ¼</li>
 </ul>

 <h3>Korunma Stratejileri</h3>
 <ol>
 <li><strong>Kan ÅŸekeri monitÃ¶rizasyonu:</strong> Sahur ve iftar Ã¶ncesi Ã¶lÃ§Ã¼m yapÄ±n</li>
 <li><strong>Kombinasyon ilaÃ§larÄ±:</strong> Ä°nsÃ¼lin/sÃ¼lfanÃ¼rea dozlarÄ± doktor kontrolÃ¼nde azaltÄ±lmalÄ±</li>
 <li><strong>Erken uyarÄ± sistemi:</strong> &lt;70 mg/dL'de oruca ara verin</li>
 <li><strong>Acil durum planÄ±:</strong> YanÄ±nÄ±zda her zaman ÅŸeker tableti bulundurun</li>
 </ol>

 <div class="info-box">
 <strong>ğŸ“± Teknoloji DesteÄŸi:</strong> SÃ¼rekli glikoz monitÃ¶rleri (CGM) kullanÄ±yorsanÄ±z, gece ve gÃ¼ndÃ¼z alarmlarÄ±nÄ±zÄ± aktif tutun. Bu sistemler hipoglisemi trendlerini erken yakalayabilir.
 </div>

 <h2 id="dehidrasyon">Dehidrasyon KorunmasÄ±</h2>

 <p>GLP-1 ilaÃ§larÄ± mide boÅŸalmasÄ±nÄ± yavaÅŸlatÄ±r ve bazÄ± hastalarda bulantÄ±/kusma yapar. Bu durum Ramazan ayÄ±nda dehidrasyon riskini artÄ±rabilir.</p>

 <h3>Risk FaktÃ¶rleri</h3>
 <ul>
 <li>GLP-1'e yeni baÅŸlayanlar (ilk 4-8 hafta)</li>
 <li>YÃ¼ksek dozlar</li>
 <li>SÄ±cak hava koÅŸullarÄ±</li>
 <li>Fiziksel aktivite</li>
 <li>Kusma/ishal Ã¶ykÃ¼sÃ¼</li>
 </ul>

 <h3>Korunma Stratejileri</h3>

 <h4>Ä°ftar-Sahur ArasÄ± SÄ±vÄ± AlÄ±mÄ±</h4>
 <table>
 <tr><th>Saat Dilimi</th><th>Hedef SÄ±vÄ±</th><th>Ã–neriler</th></tr>
 <tr><td><strong>Ä°ftar (18:30)</strong></td><td>500 mL</td><td>IlÄ±k su + hurma/tuz</td></tr>
 <tr><td><strong>AkÅŸam (20:00)</strong></td><td>400 mL</td><td>Ã‡orba + ayran</td></tr>
 <tr><td><strong>Gece (22:00)</strong></td><td>300 mL</td><td>Bitki Ã§ayÄ±</td></tr>
 <tr><td><strong>Sahur (05:30)</strong></td><td>400 mL</td><td>Su + sÃ¼t</td></tr>
 <tr><td><strong>Toplam</strong></td><td><strong>1.6 L</strong></td><td>Minimum hedef</td></tr>
 </table>

 <div class="warning-box">
 <strong>âš ï¸ Dikkat Edilecek Durumlar:</strong><br>
 â€¢ Koyu renk idrar<br>
 â€¢ 8 saatten uzun idrar Ã§Ä±karamama<br>
 â€¢ BaÅŸ dÃ¶nmesi, halsizlik<br>
 â€¢ Kuru aÄŸÄ±z, dudaklar<br>
 Bu belirtiler varsa oruca ara verin ve sÄ±vÄ± alÄ±n.
 </div>

 <h2 id="protein">Protein Hedefleri</h2>

 <div class="key-stat-box"><span class="ks-number">1.2-1.6</span><span class="ks-context">ESPEN kÄ±lavuzlarÄ±na gÃ¶re obez hastalarda gÃ¼nlÃ¼k protein hedefi (g/kg vÃ¼cut aÄŸÄ±rlÄ±ÄŸÄ±). GLP-1 ile kilo verme sÄ±rasÄ±nda kas koruma iÃ§in kritik Ã¶nemde ğŸŸ¢</span></div>

 <h3>Neden Bu Kadar Ã–nemli?</h3>
 <p>GLP-1 ilaÃ§larÄ±yla kaybedilen kilonun %25-40'Ä± yaÄŸsÄ±z kÃ¼tleden (kas + organ) gelebilir. Ramazan ayÄ±nda beslenme penceresinin daraldÄ±ÄŸÄ± dÃ¶nemde, yeterli protein alÄ±mÄ± kas koruma aÃ§Ä±sÄ±ndan kritik hale gelir.</p>

 <h3>Pratik Hesaplama</h3>
 <ul>
 <li><strong>80 kg hasta:</strong> 96-128 g protein/gÃ¼n (80 Ã— 1.2-1.6)</li>
 <li><strong>100 kg hasta:</strong> 120-160 g protein/gÃ¼n</li>
 <li><strong>60 kg hasta:</strong> 72-96 g protein/gÃ¼n</li>
 </ul>

 <h3>Ä°ftar-Sahur DaÄŸÄ±lÄ±mÄ±</h3>
 
 <table>
 <tr><th>Ã–ÄŸÃ¼n</th><th>Protein Hedefi</th><th>Kaynak Ã–rnekleri</th><th>Pratik Ã–lÃ§Ã¼</th></tr>
 <tr><td><strong>Ä°ftar</strong></td><td>40-50 g</td><td>150g tavuk gÃ¶ÄŸsÃ¼ + 200ml sÃ¼t</td><td>AvuÃ§ iÃ§i et + 1 bardak sÃ¼t</td></tr>
 <tr><td><strong>AkÅŸam</strong></td><td>20-30 g</td><td>30g ceviz + 150g yoÄŸurt</td><td>1 avuÃ§ kuruyemiÅŸ + 1 kase yoÄŸurt</td></tr>
 <tr><td><strong>Sahur</strong></td><td>25-35 g</td><td>2 yumurta + 30g peynir + 200ml sÃ¼t</td><td>2 yumurta + 2 kibrit kutusu peynir</td></tr>
 </table>

 <div class="success-box">
 <strong>ğŸ¥© YÃ¼ksek Kaliteli Protein KaynaklarÄ±:</strong><br>
 â€¢ <strong>Tam protein:</strong> Et, tavuk, balÄ±k, yumurta, sÃ¼t Ã¼rÃ¼nleri<br>
 â€¢ <strong>Bitkisel:</strong> Mercimek+pirinÃ§, nohut, kinoa, hemp tohumu<br>
 â€¢ <strong>Destekler:</strong> Whey protein tozu (sahurda kolay)
 </div>

 <h3>GLP-1 KullanÄ±cÄ±larÄ± Ä°Ã§in Ã–zel Ä°puÃ§larÄ±</h3>
 <ul>
 <li><strong>KÃ¼Ã§Ã¼k porsiyonlar:</strong> Protein yoÄŸun ama hacim olarak kÃ¼Ã§Ã¼k seÃ§imler yapÄ±n</li>
 <li><strong>SÄ±vÄ± formda:</strong> Protein shake'leri mide Ã¼zerinde daha az yÃ¼k oluÅŸturur</li>
 <li><strong>YavaÅŸ yemek:</strong> 20-30 dakikada bitirin, acele etmeyin</li>
 <li><strong>Ã–nce protein:</strong> Ã–ÄŸÃ¼ne proteinden baÅŸlayÄ±n, sonra karbonhidrat</li>
 </ul>

 <h2 id="pratik">Pratik Ã–neriler</h2>

 <h3>Ä°ftar Rutini</h3>
 <ol>
 <li><strong>AÃ§Ä±lÄ±ÅŸ (5 dakika):</strong> 1-2 hurma + 1 bardak Ä±lÄ±k su</li>
 <li><strong>Namaz molasÄ± (20 dakika)</strong></li>
 <li><strong>Ana Ã¶ÄŸÃ¼n (30 dakika):</strong> Ã‡orba â†’ protein â†’ sebze â†’ az karbonhidrat</li>
 <li><strong>Bekletme (2 saat):</strong> Sindirime zaman tanÄ±yÄ±n</li>
 <li><strong>AtÄ±ÅŸtÄ±rmalÄ±k:</strong> YoÄŸurt, kuruyemiÅŸ, meyve</li>
 </ol>

 <h3>Sahur Stratejisi</h3>
 <div class="info-box">
 <strong>â° Sahur ZamanlamasÄ±:</strong><br>
 GLP-1 kullanÄ±cÄ±larÄ± iÃ§in sahuru imsaka 45-60 dakika kala yapmak optimal. Bu ÅŸekilde mide boÅŸalmasÄ± iÃ§in yeterli zaman kalÄ±r.
 </div>

 <p><strong>Ä°deal Sahur MenÃ¼sÃ¼:</strong></p>
 <ul>
 <li>2 yumurta (omlet/haÅŸlanmÄ±ÅŸ)</li>
 <li>1 dilim tam tahÄ±l ekmek</li>
 <li>2 kibrit kutusu peynir</li>
 <li>1 bardak sÃ¼t/ayran</li>
 <li>5-6 zeytin</li>
 <li>SalatalÄ±k, domates</li>
 </ul>

 <h3>Egzersiz Rehberi</h3>
 
 <table>
 <tr><th>Egzersiz TÃ¼rÃ¼</th><th>Zamanlama</th><th>SÃ¼re</th><th>YoÄŸunluk</th></tr>
 <tr><td><strong>YÃ¼rÃ¼yÃ¼ÅŸ</strong></td><td>Ä°ftar Ã¶ncesi 1 saat</td><td>20-30 dk</td><td>Hafif-orta</td></tr>
 <tr><td><strong>DirenÃ§</strong></td><td>Ä°ftar sonrasÄ± 2-3 saat</td><td>30-40 dk</td><td>Orta</td></tr>
 <tr><td><strong>Yoga/Germe</strong></td><td>Sahur Ã¶ncesi</td><td>15-20 dk</td><td>Hafif</td></tr>
 </table>

 <div class="warning-box">
 <strong>âš ï¸ Egzersiz UyarÄ±larÄ±:</strong><br>
 â€¢ SÄ±cak saatlerde aÃ§Ä±k havada egzersiz yapmayÄ±n<br>
 â€¢ BaÅŸ dÃ¶nmesi, Ã§arpÄ±ntÄ± hissettiÄŸinizde durun<br>
 â€¢ Ä°lk hafta egzersiz yoÄŸunluÄŸunu %50 azaltÄ±n
 </div>

 <h2 id="doktor">Doktor KontrolÃ¼</h2>

 <h3>Ramazan Ã–ncesi DeÄŸerlendirme (4-6 Hafta Ã–nce)</h3>
 
 <div class="info-box">
 <strong>ğŸ“‹ Kontrol Listesi:</strong><br>
 âœ… HbA1c, aÃ§lÄ±k glukoz<br>
 âœ… BÃ¶brek fonksiyonlarÄ± (<a href="supplement-tier-list-bilimsel-kanit-puanlama.html" style="color:#0D7377; text-decoration:underline; text-decoration-color:rgba(13,115,119,0.3); text-underline-offset:2px;">kreatin</a>in, eGFR)<br>
 âœ… KaraciÄŸer fonksiyonlarÄ±<br>
 âœ… Elektrolit dengesi<br>
 âœ… Kan basÄ±ncÄ± deÄŸerlendirmesi<br>
 âœ… Hipoglisemi risk skoru<br>
 âœ… Ä°laÃ§ dozlarÄ±nÄ±n gÃ¶zden geÃ§irilmesi
 </div>

 <h3>Ramazan SÄ±rasÄ± Takip</h3>
 <ul>
 <li><strong>1. hafta:</strong> GÃ¼nlÃ¼k kan ÅŸekeri Ã¶lÃ§Ã¼mÃ¼</li>
 <li><strong>2-4. hafta:</strong> Haftada 2-3 kez Ã¶lÃ§Ã¼m</li>
 <li><strong>Problem durumunda:</strong> 24 saat iÃ§inde doktor gÃ¶rÃ¼ÅŸÃ¼</li>
 </ul>

 <h3>Acil Durum Kriterleri</h3>
 
 <div class="warning-box">
 <strong>ğŸš¨ Derhal Oruca Ara Verin:</strong><br>
 â€¢ Kan ÅŸekeri &lt;70 mg/dL<br>
 â€¢ Kan ÅŸekeri &gt;300 mg/dL<br>
 â€¢ Åiddetli bulantÄ±/kusma<br>
 â€¢ BaÅŸ dÃ¶nmesi, bayÄ±lma hissi<br>
 â€¢ GÃ¶ÄŸÃ¼s aÄŸrÄ±sÄ±<br>
 â€¢ Nefes darlÄ±ÄŸÄ±
 </div>

 <h3>Ramazan SonrasÄ±</h3>
 <p>Ramazan ayÄ± bittiÄŸinde normal beslenme dÃ¼zenine geÃ§erken:</p>
 <ul>
 <li>Ä°laÃ§ zamanlamasÄ±nÄ± eski haline getirin</li>
 <li>Doz artÄ±rÄ±m planlarÄ±nÄ± doktor ile gÃ¶rÃ¼ÅŸÃ¼n</li>
 <li>Kilo ve kan ÅŸekeri kontrolÃ¼ yaptÄ±rÄ±n</li>
 <li>Gerekirse beslenme uzmanÄ±ndan destek alÄ±n</li>
 </ul>

 <h2>SonuÃ§ ve Ã–nemli HatÄ±rlatmalar</h2>

 <div class="key-stat-box"><span class="ks-number">0.80</span><span class="ks-context"><a href="semaglutide-ve-kalp-sagligi-select-calismasi-sonuclari.html" style="color:#0D7377; text-decoration:underline; text-decoration-color:rgba(13,115,119,0.3); text-underline-offset:2px;">SELECT Ã§alÄ±ÅŸmasÄ±</a>nda semaglutid ile majÃ¶r kardiyovaskÃ¼ler olay riskinde azalma (HR 0.80, %95 GA 0.72-0.90, p&lt;0.001) â€” kalp saÄŸlÄ±ÄŸÄ± iÃ§in ek fayda ğŸŸ¢</span></div>

 <p>GLP-1 ilaÃ§larÄ±yla Ramazan orucunun gÃ¼venle tutulabileceÄŸi bilimsel olarak kanÄ±tlanmÄ±ÅŸ. Ancak bu, uygun hasta seÃ§imi, doÄŸru planlama ve yakÄ±n takip ile mÃ¼mkÃ¼n.</p>

 <div class="success-box">
 <strong>âœ… Ana Prensipler:</strong><br>
 â€¢ <strong>GÃ¼venlik Ã¶ncelik:</strong> Hipoglisemi belirtilerinde oruca ara verin<br>
 â€¢ <strong>PlanlÄ± yaklaÅŸÄ±m:</strong> Ramazan Ã¶ncesi 4-6 hafta doktor kontrolÃ¼<br>
 â€¢ <strong>Stabil doz:</strong> Ramazan ayÄ±nda doz deÄŸiÅŸtirmeyin<br>
 â€¢ <strong>Yeterli protein:</strong> 1.2-1.6 g/kg hedefini koruyun<br>
 â€¢ <strong>Hidratasyon:</strong> Ä°ftar-sahur arasÄ± minimum 1.6L sÄ±vÄ±
 </div>

 <div class="quote-box">
 <strong>ğŸ“– UnutmayÄ±n:</strong> Bu rehber genel bilgilendirme amaÃ§lÄ±dÄ±r. Her hastanÄ±n durumu farklÄ±dÄ±r ve kiÅŸiselleÅŸtirilmiÅŸ tedavi planÄ± gerekir. GLP-1 ilaÃ§larÄ± ile Ramazan orucunu gÃ¼venle geÃ§irmek iÃ§in mutlaka doktorunuz ile detaylÄ± gÃ¶rÃ¼ÅŸÃ¼n.
 </div>

 <h2>Kaynaklar</h2>
 <ol style="font-size:0.9rem;color:#6b7280;">
 <li>Alsairafi ZK, et al. Glucagon-Like Peptide-1 (GLP-1) during Ramadan: Narrative Review of the Published Literature. <em>Diabetes Ther.</em> 2024;15(1):23-45. <span class="evidence-label evidence-high">ğŸŸ¢</span></li>
 <li>Rahman MM, et al. Safety and effectiveness of tirzepatide during Ramadan fasting: Real-world evidence from patients with type 2 diabetes in Bangladesh. <em>Diabetes Obes Metab.</em> 2026;28(3):456-463. <span class="evidence-label evidence-high">ğŸŸ¢</span></li>
 <li>Jabbar A, et al. Safety and efficacy of glucagon-like peptide-1 receptor agonists in individuals with type 2 diabetes mellitus fasting during Ramadan: a systematic review and meta-analysis. <em>Lancet Diabetes Endocrinol.</em> 2025;13(12):987-996. <span class="evidence-label evidence-high">ğŸŸ¢</span></li>
 <li>Ibrahim A, et al. Recommendations for the Management of Diabetes During Ramadan Applying the Principles of the ADA/EASD Consensus: Update 2025. <em>Diabetes Metab Res Rev.</em> 2025;41(6):e3789. <span class="evidence-label evidence-high">ğŸŸ¢</span></li>
 <li>ESPEN Guidelines on Clinical Nutrition in Obesity. <em>Clin Nutr.</em> 2022;41(12):2799-2831. <span class="evidence-label evidence-high">ğŸŸ¢</span></li>
 <li>Cederholm T, et al. ESPEN practical guideline: Clinical nutrition and hydration in geriatrics. <em>Clin Nutr.</em> 2022;41(4):958-989. <span class="evidence-label evidence-high">ğŸŸ¢</span></li>
 <li>OECD Health Statistics 2024. Obesity rates by country. <span class="evidence-label evidence-moderate">ğŸŸ¡</span></li>
 <li>Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity (SELECT). <em>N Engl J Med.</em> 2023;389:2221-2232. <span class="evidence-label evidence-high">ğŸŸ¢</span></li>
 </ol>

 <div style="background:linear-gradient(135deg,#f0fdfa,#ecfdf5);border:2px solid #0D7377;border-radius:16px;padding:2rem;text-align:center;margin:2rem 0;">
  <p style="font-size:1.1rem;font-weight:700;color:#0D7377;margin-bottom:0.5rem;">ğŸŒ™ Ramazan Size Uygun mu?</p>
  <p style="font-size:0.95rem;color:#374151;margin-bottom:1rem;">GLP-1 kullanÄ±cÄ±larÄ± iÃ§in kiÅŸiselleÅŸtirilmiÅŸ oruÃ§ risk deÄŸerlendirmesi.</p>
  <a href="../araclar/ramazan-risk-hesaplayici.html" style="display:inline-block;background:#0D7377;color:white;padding:0.75rem 2rem;border-radius:10px;text-decoration:none;font-weight:600;">Risk Hesapla â†’</a>
 </div>

 </div>
 

<!-- Ä°LGÄ°LÄ° YAZILAR - Auto-generated by internal-links.js -->
<div class="related-posts-section" style="margin-top:3rem; padding-top:2rem; border-top:2px solid #e5e7eb;">
  <div style="display:flex; align-items:center; gap:12px; margin-bottom:1.5rem;">
    <div style="width:4px; height:32px; background:linear-gradient(to bottom, #0D7377, #14919B); border-radius:2px;"></div>
    <h2 style="margin:0; font-family:'Playfair Display', serif; font-size:1.5rem; color:#195157;">Ä°lgili YazÄ±lar</h2>
  </div>
  <div style="display:flex; flex-wrap:wrap; gap:1rem;">

      <a href="glp1-ilaclari-kanser-riskini-artirir-mi-guncel-bilimsel-veri.html" class="related-post-card" style="text-decoration:none; color:inherit; display:block; background:#fff; border:1px solid #e5e7eb; border-radius:12px; padding:1.25rem; transition:all 0.2s ease; flex:1; min-width:250px;">
        <div style="display:flex; align-items:center; gap:8px; margin-bottom:0.75rem;">
          <span style="font-size:1.2rem;">ğŸ’Š</span>
          <span style="font-size:0.75rem; font-weight:600; color:#EC4899; text-transform:uppercase; letter-spacing:0.5px;">Tedavi</span>
        </div>
        <h4 style="font-size:0.95rem; font-weight:600; color:#195157; margin-bottom:0.5rem; line-height:1.4;">GLP-1 Ä°laÃ§larÄ± Kanser Riskini ArtÄ±rÄ±r mÄ±? GÃ¼ncel Bilimsel Veriler</h4>
        <p style="font-size:0.85rem; color:#6B7280; line-height:1.5; margin:0;">GLP-1 reseptÃ¶r agonistlerinin kanser riskine etkisi hakkÄ±nda 2025'in en gÃ¼ncel meta-analiz bulgularÄ±nÄ± inceleyen kapsamlâ€¦</p>
      </a>

      <a href="semaglutid-ve-pankreatit-riski-vaka-raporlari-isiginda-guven.html" class="related-post-card" style="text-decoration:none; color:inherit; display:block; background:#fff; border:1px solid #e5e7eb; border-radius:12px; padding:1.25rem; transition:all 0.2s ease; flex:1; min-width:250px;">
        <div style="display:flex; align-items:center; gap:8px; margin-bottom:0.75rem;">
          <span style="font-size:1.2rem;">ğŸ’Š</span>
          <span style="font-size:0.75rem; font-weight:600; color:#EC4899; text-transform:uppercase; letter-spacing:0.5px;">Tedavi</span>
        </div>
        <h4 style="font-size:0.95rem; font-weight:600; color:#195157; margin-bottom:0.5rem; line-height:1.4;">Semaglutid ve Pankreatit Riski: Vaka RaporlarÄ± IÅŸÄ±ÄŸÄ±nda GÃ¼venlik</h4>
        <p style="font-size:0.85rem; color:#6B7280; line-height:1.5; margin:0;">Semaglutid kullanÄ±mÄ± sÄ±rasÄ±nda akut pankreatit riski ve gÃ¼venlik Ã¶nlemleri. GÃ¼ncel vaka raporlarÄ± ve araÅŸtÄ±rma bulgularÄ±â€¦</p>
      </a>

      <a href="tirzepatide-yeni-nesil-kilo-verme-ilacinin-bilimsel-gercekle.html" class="related-post-card" style="text-decoration:none; color:inherit; display:block; background:#fff; border:1px solid #e5e7eb; border-radius:12px; padding:1.25rem; transition:all 0.2s ease; flex:1; min-width:250px;">
        <div style="display:flex; align-items:center; gap:8px; margin-bottom:0.75rem;">
          <span style="font-size:1.2rem;">ğŸ’Š</span>
          <span style="font-size:0.75rem; font-weight:600; color:#EC4899; text-transform:uppercase; letter-spacing:0.5px;">Tedavi</span>
        </div>
        <h4 style="font-size:0.95rem; font-weight:600; color:#195157; margin-bottom:0.5rem; line-height:1.4;">Tirzepatide: Yeni Nesil Kilo Verme Ä°lacÄ±nÄ±n Bilimsel GerÃ§ekleri</h4>
        <p style="font-size:0.85rem; color:#6B7280; line-height:1.5; margin:0;">Tirzepatide (Mounjaro/Zepbound) ile ilgili gÃ¼ncel araÅŸtÄ±rmalar, etkinlik oranlarÄ± ve TÃ¼rkiye'deki durum hakkÄ±nda kapsamlâ€¦</p>
      </a>
  </div>
  <style>
    .related-post-card:hover { transform:translateY(-2px); box-shadow:0 4px 12px rgba(0,0,0,0.1); border-color:#14919B !important; }
    @media(max-width:768px) { .related-post-card { min-width:100% !important; } }
  </style>
</div>
<!-- END Ä°LGÄ°LÄ° YAZILAR -->

</article>

 <div class="cta-box">
 <h3>Size uygun tedavi seÃ§eneÄŸini Ã¶ÄŸrenin</h3>
 <p>KiÅŸiselleÅŸtirilmiÅŸ deÄŸerlendirme iÃ§in testimizi tamamlayÄ±n</p>
 <a href="../test.html" class="cta-btn">Teste BaÅŸla â†’</a>
 </div>

 <div class="author-box">
 <div class="author-avatar">UY</div>
 <div class="author-info">
 <h4>UzunYaÅŸa EditÃ¶ryal Ekibi</h4>
 <p>TÄ±bbi Ä°nceleme: Gastroenteroloji ve Endokrinoloji UzmanlarÄ± DanÄ±ÅŸma Kurulu</p>
 </div>
 </div>

 <footer><p style="font-size:0.85rem;font-style:italic;opacity:0.7;margin-bottom:0.5rem;">TÃ¼rkiye uzun yaÅŸasÄ±n diye.</p><p>Â© 2026 UzunYaÅŸa. <a href="https://tyzd.org" target="_blank" style="color:inherit;text-decoration:underline;">TÄ±pta Yapay Zeka DerneÄŸi</a> giriÅŸimidir.</p></footer>
<script src="../../scripts/animations.js" defer></script>
<script src="/scripts/premium-animations.js" defer></script>
</body>
</html>